Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
HYTRIN |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α1-blocker (quinazoline). |
| Generic Name |
|
Terazosin (as HCl) 1mg, 2mg, 5mg, 10mg; caps. |
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
1 mg at bedtime, then increase slowly. Usually: 1–5 mg once daily in the AM; max 20 mg/day. Monitor at peak (2–3 hours after dose) and trough. If BP response is substantially diminished at 24 hours, may increase dose or give in 2 divided doses. If hypotensive effects occur at peak, consider twice daily dosing. If another antihypertensive is added, dosage reduction and retitration may be necessary. |
| Precautions |
|
Syncope. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Caution with verapamil, other antihypertensives. |
| Adverse Reactions |
|
Syncope (esp. 1st dose), dizziness, somnolence, asthenia, nausea, nasal congestion, palpitations, orthostatic hypotension, blurred vision, peripheral edema; priapism (rare). |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
